Key points are not available for this paper at this time.
Mesenchymal stem cells (MSCs) are partially defined by their ability to differentiate into tissues including bone, cartilage and adipose in vitro, but it is their trophic, paracrine and immunomodulatory functions that may have the greatest therapeutic impact in vivo. Unlike pharmaceutical treatments that deliver a single agent at a specific dose, MSCs are site regulated and secrete bioactive factors and signals at variable concentrations in response to local microenvironmental cues. Significant progress has been made in understanding the biochemical and metabolic mechanisms and feedback associated with MSC response. The anti-inflammatory and immunomodulatory capacity of MSC may be paramount in the restoration of localized or systemic conditions for normal healing and tissue regeneration. Allogeneic MSC treatments, categorized as a drug by regulatory agencies, have been widely pursued, but new studies demonstrate the efficacy of autologous MSC therapies, even for individuals affected by a disease state. Safety and regulatory concerns surrounding allogeneic cell preparations make autologous and minimally manipulated cell therapies an attractive option for many regenerative, anti-inflammatory and autoimmune applications.
Building similarity graph...
Analyzing shared references across papers
Loading...
Matthew B. Murphy
RegeneRx Biopharmaceuticals (United States)
Kathryn Moncivais
Cellectar Biosciences (United States)
Arnold I. Caplan
Florida State University
Experimental & Molecular Medicine
Case Western Reserve University
Cellectar Biosciences (United States)
Building similarity graph...
Analyzing shared references across papers
Loading...
Murphy et al. (Fri,) studied this question.
synapsesocial.com/papers/69d8983c52654bb436d19714 — DOI: https://doi.org/10.1038/emm.2013.94
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: